The Tecan Group announced a planned CEO transition, marking a new chapter in the company's successful growth story. After nearly 12 years with Tecan, including 6 years as CEO, Dr. Achim von Leoprechting has decided to step down as CEO, effective August 1, 2025, to focus on new projects. Dr. von Leoprechting will remain available to the Group in an advisory capacity, ensuring a smooth transition and leveraging his extensive industry and company-specific knowledge.
The Board of Directors has appointed Monica Manotas, a member of the Board since April 2024, as the new CEO of Tecan, who will assume her new position on August 1, 2025. As a Board member, Ms. Manotas is already well acquainted with Tecan's business. She also brings many years of international experience in the life sciences industry, including over 20 years in executive positions at Thermo Fisher Scientific.
At that time, she will step down from the Board and the Audit Committee. The Audit Committee will continue with its two remaining members: Matthias Gillner, who will remain Chair, and Dr. Lukas Braunschweiler. A diligent handover and transition process will take place in close cooperation between Dr. von Leoprechting and Ms. Manotas.
Monica Manotas Monica Manotas worked at Thermo Fisher Scientific, one of the world's largest providers of products and services for laboratories and clinics, from 1999 to 2023, most recently as Senior Vice President and President, Life Sciences and Laboratory Products Group. In her various specialist and management roles, including in finance, Ms. Manotas has worked in France, Spain, the USA, and Switzerland. The Colombian and US citizen holds a university degree in industrial engineering and an MBA in Finance.
